Lyme Disease- Market Growth, Insights, Development Stage and Review 2019

Albany, US, 2019-Sep-30 — /EPR Network/ —The global market status for Lyme disease is precisely examined through a smart research report added to the broad database managed by Market Research Hub (MRH). This study is titled “Lyme Disease-Pipeline Review, H2 2019”, which tends to deliver in-depth knowledge associated to the Lyme disease for the present and forecasted period until 2025. Furthermore, the report examines the target market based on market size, revenue and geography; making it quite useful for the readers.

Get Sample Copy at

Lyme disease – Pipeline Review, H2 2019


Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Lyme disease – Pipeline Review, H2 2019, provides an overview of the Lyme disease (Infectious Disease) pipeline landscape.

Lyme disease is a bacterial infection transmitted by a tick. Lyme disease is caused by the bacterium Borrelia burgdorferi. Symptoms include rash, fever, chills, fatigue, body aches and headache. Risk factors include age, gender and geographic locations. Treatment includes antibiotics.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Lyme Disease – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Lyme Disease (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Lyme disease (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Lyme disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Lyme disease (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.


– The pipeline guide provides a snapshot of the global therapeutic landscape of Lyme disease (Infectious Disease).
– The pipeline guide reviews pipeline therapeutics for Lyme disease (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Lyme disease (Infectious Disease) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Lyme disease (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Lyme Disease (Infectious Disease)

Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Lyme disease (Infectious Disease).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Lyme disease (Infectious Disease) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Top of Form

Browse Complete Report at

Table of Contents
List of Tables
List of Figures
Global Markets Direct Report Coverage
Lyme Disease – Overview
Lyme Disease – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Lyme Disease – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Lyme Disease – Companies Involved in Therapeutics Development
Inovio Pharmaceuticals Inc
NovoBiotic Pharmaceuticals LLC
Valneva SE
Lyme Disease – Drug Profiles
azithromycin – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Inhibit CRASP1 for Lyme Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
desloratadine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Inhibit OspA for Lyme Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lyme disease vaccine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lyme disease vaccine 2 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit Outer Surface Protein A for Lyme Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Lyme Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Lyme Disease – Drug Profile
Product Description
Mechanism Of Action

Make An Enquiry About This Report

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports of different sector like Pharmaceuticals market research   and analysis. MRH’s expansive collection of industry reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us

90 State Street,

Albany, NY 12207,

United States

Toll Free: 800-998-4852 (US-Canada)



Read Industry News at:


Matched content

Editor’s pick

Express Press Release Distribution